Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect
- 25 September 2001
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 32 (3) , 195-202
- https://doi.org/10.1002/gcc.1183
Abstract
Multiple primary cancers are one of the hallmarks of inherited predisposition. Outside the familial context, multiple primary tumors could be related either to germline de novo mutations or to low‐penetrance mutations, in predisposing genes. We selected 100 patients who displayed multiple primary melanoma (MPM) without any known melanoma cases recorded within their families and looked for germline mutations in the two melanoma‐predisposing genes identified to date, CDKN2A and CDK4 exon 2. Nine patients (9%) had germline mutations in CDKN2A, whereas none carried germline mutations in exon 2 of CDK4. Seven cases displayed a recurrent missense mutation, G101W, already described in more than 20 melanoma‐prone families; one case carried a missense mutation never reported to date (P114S), and the last case was a carrier of a 6 bp insertion at nucleotide 57 resulting in a duplication of codons 18 and 19. To ascertain whether the G101W was a mutational hot spot for de novo mutations or a common founder mutation, we genotyped eight microsatellite markers flanking the CDKN2A gene. After allowing for recombination over time, haplotype sharing provided evidence for an original G101W mutation common to 6 out of 7 sporadic MPM cases. Therefore, it can be concluded that de novo germline CDKN2A mutations associated with MPM are rare.Keywords
Funding Information
- AP-HP (CRC96011)
- Fondation Sanofi Vaincre le Mélanome
- Association pour la Recherche contre le Cancer (ARC) Subvention libre 1998
This publication has 29 references indexed in Scilit:
- Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure informationOncogene, 1999
- Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus)Melanoma Research, 1999
- Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group [published erratum appears in Hum Mol Genet 1998 May;7(5):941]Human Molecular Genetics, 1998
- Point mutations can inactivate in vitro and in vivo activities of p16INK4a/CDKN2A in human gliomaOncogene, 1997
- Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumorsGastroenterology, 1996
- A Familial Syndrome of Pancreatic Cancer and Melanoma with a Mutation in theCDKN2Tumor-Suppressor GeneNew England Journal of Medicine, 1995
- Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibitionNature, 1995
- A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor TypesScience, 1994
- Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancersNature, 1994
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993